David Lubkowicz

838 total citations · 1 hit paper
11 papers, 620 citations indexed

About

David Lubkowicz is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Lubkowicz has authored 11 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 3 papers in Pathology and Forensic Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Lubkowicz's work include Kidney Stones and Urolithiasis Treatments (3 papers), Metabolism and Genetic Disorders (3 papers) and Gut microbiota and health (3 papers). David Lubkowicz is often cited by papers focused on Kidney Stones and Urolithiasis Treatments (3 papers), Metabolism and Genetic Disorders (3 papers) and Gut microbiota and health (3 papers). David Lubkowicz collaborates with scholars based in United States and Singapore. David Lubkowicz's co-authors include Vincent M. Isabella, Mary Joan Castillo, Caroline Kurtz, Dean Falb, Ning Li, Yves Millet, Sarah E. Rowe, Adam Fisher, Paul Miller and Kip A. West and has published in prestigious journals such as Nature Communications, Nature Biotechnology and Gastroenterology.

In The Last Decade

David Lubkowicz

10 papers receiving 599 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria

2018 403 citations Vincent M. Isabella, Mary Joan Castillo et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Lubkowicz United States	6	417	140	129	105	89	11	620
Mary Joan Castillo United States	7	458 1.1×	147 1.1×	142 1.1×	110 1.0×	102 1.1×	10	673
Adam Fisher United States	5	434 1.0×	294 2.1×	260 2.0×	92 0.9×	133 1.5×	10	810
Jonathan W. Kotula United States	8	782 1.9×	176 1.3×	212 1.6×	135 1.3×	193 2.2×	8	1.0k
Lisa G. McWilliams United States	13	330 0.8×	124 0.9×	36 0.3×	22 0.2×	67 0.8×	16	769
Jon C. Rees United States	16	284 0.7×	32 0.2×	112 0.9×	31 0.3×	33 0.4×	32	689
Grischa Y. Chen United States	10	297 0.7×	58 0.4×	19 0.1×	69 0.7×	71 0.8×	15	479
Matvei Khoroshkin United States	7	388 0.9×	27 0.2×	28 0.2×	120 1.1×	71 0.8×	9	507
Eiichiro Kimura Japan	19	888 2.1×	40 0.3×	180 1.4×	65 0.6×	365 4.1×	30	1.2k
Thomas Ishoey United States	7	417 1.0×	40 0.3×	141 1.1×	27 0.3×	45 0.5×	9	659

Countries citing papers authored by David Lubkowicz

Since Specialization

Citations

This map shows the geographic impact of David Lubkowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lubkowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lubkowicz more than expected).

Fields of papers citing papers by David Lubkowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lubkowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lubkowicz. The network helps show where David Lubkowicz may publish in the future.

Co-authorship network of co-authors of David Lubkowicz

This figure shows the co-authorship network connecting the top 25 collaborators of David Lubkowicz. A scholar is included among the top collaborators of David Lubkowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lubkowicz. David Lubkowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Perreault, Mylène, Michael J. James, Sean L. Cotton, et al.. (2024). The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers. Cell Host & Microbe. 32(3). 382–395.e10. 23 indexed citations

Lubkowicz, David, David L. Hava, Kim Lewis, & Vincent M. Isabella. (2024). Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors. ACS Synthetic Biology. 13(4). 1077–1084. 4 indexed citations

Lubkowicz, David, Michael J. James, Ron B. Shmueli, et al.. (2022). An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria. Molecular Systems Biology. 18(3). e10539–e10539. 35 indexed citations

Perreault, Mylène, Michael J. James, Michael J. Jessel, et al.. (2022). ACTIVITY OF SYNB1353, AN INVESTIGATIONAL METHIONINE-CONSUMING SYNTHETIC BIOTIC MEDICINE, IN AN ACUTE NONHUMAN PRIMATE MODEL OF HOMOCYSTINURIA. Molecular Genetics and Metabolism. 135(4). 292–293. 3 indexed citations

Reeves, Analise Z., Starsha Kolodziej, Chun‐Cheih Chao, et al.. (2022). Sa1654: ENGINEERING SYNTHETIC BIOTIC MEDICINES TO SECRETE HUMAN PROTEINS AND SHORT CHAIN FATTY ACIDS AS A VERSATILE PLATFORM TO TREAT INFLAMMATORY BOWEL DISEASE. Gastroenterology. 162(7). S–455. 1 indexed citations

Charbonneau, Mark R., et al.. (2021). Characterization of an engineered live bacterial therapeutic for the treatment of phenylketonuria in a human gut-on-a-chip. Nature Communications. 12(1). 2805–2805. 54 indexed citations

Puurunen, Marja, William S. Denney, Andrew Marsh, et al.. (2021). PD21-10 SAFETY AND TOLERABILITY OF AN OXALATE-CONSUMING SYNTHETIC BIOTIC MEDICINE: SYNB8802 IN HEALTHY VOLUNTEERS WITH INDUCED DIETARY HYPEROXALURIA. The Journal of Urology. 206(Supplement 3). 1 indexed citations

Lubkowicz, David, Michael J. James, Mark R. Charbonneau, et al.. (2020). Development of a Synthetic Biotic, SYNB8802, for the Treatment of Enteric Hyperoxaluria. Journal of the American Society of Nephrology. 31(10S). 245–245.

Isabella, Vincent M., Mary Joan Castillo, David Lubkowicz, et al.. (2018). Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nature Biotechnology. 36(9). 857–864. 403 indexed citations breakdown →

10.

Lubkowicz, David, Chun Loong Ho, In Young Hwang, et al.. (2018). Reprogramming Probiotic Lactobacillus reuteri as a Biosensor for Staphylococcus aureus Derived AIP-I Detection. ACS Synthetic Biology. 7(5). 1229–1237. 67 indexed citations

11.

Lubkowicz, David, et al.. (2015). Transplantability of a circadian clock to a noncircadian organism. Science Advances. 1(5). 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact